Trials / Completed
CompletedNCT02456038
Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)
A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Patients With Hypophosphatasia (HPP)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess safety and efficacy of Asfotase Alfa (ALXN1215) in patients with hypophosphatasia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asfotase Alfa (ALXN1215) |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2015-05-28
- Last updated
- 2016-03-31
Locations
12 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02456038. Inclusion in this directory is not an endorsement.